We are seeing patients in-person and through Video Visits. Learn more about how we’re keeping you safe and please review our updated visitor policy. Please also consider supporting Weill Cornell Medicine’s efforts to support our front-line workers.


Phosphorous-32 (P-32) is a radioactive isotope of phosphorus that is rarely used to treat MPNs to control blood counts. It is delivered intravenously (IV). As a radiopharmaceutical, P-32 accumulates in cells that are dividing and can be used to deliver radiation to cancerous tissues in the bone marrow, killing these cells by interfering with the cellular DNA.

P-32 can be used at varying doses and can be a highly effective treatment for MPNs, inducing long-term remissions in some patients. However, because it can damage DNA, P-32 treatment is thought to increase the risk of leukemic transformation and for this reason is usually reserved for treating older patients only under special circumstances.

P-32 is most often used in patients with polycythemia vera (PV) who are unresponsive or intolerant of other therapies (e.g., hydroxyurea, interferon, ruxolitinib) and/or phlebotomy.

Side Effects

Common side effects:

  • Decreased blood counts
  • Diarrhea
  • Fever
  • Nausea or vomiting

Additional Information: https://www.drugs.com/sfx/sodium-phosphate-p32-side-effects.html

Richard T. Silver MD Myeloproliferative Neoplasms Center 525 East 70th St., Starr Pavillion, 3rd Floor New York, NY 10021 SilverMPNCenter@med.cornell.edu